DDR1 Specific Neutra™ Antibody Products

Are you encountering obstacles in targeting collagen-driven tumor immune evasion or prolonged drug development timelines? Creative Biolabs' DDR1 specific Neutra™ antibody products leverage advanced structural biology insights and hybridoma screening to deliver highly selective, high-affinity antibodies that disrupt collagen-DDR1 interactions, enabling efficient immunotherapy development and robust preclinical outcomes.

Introduction to DDR1

Discoidin domain receptor tyrosine kinase 1 (DDR1) is a collagen-activated receptor tyrosine kinase central to cellular adhesion, extracellular matrix remodeling, and tumor microenvironment modulation. Its dysregulation is strongly implicated in cancer progression, fibrosis, and immune evasion.

• Basic Information

DDR1 is a transmembrane receptor highly expressed in epithelial cells and overactivated in aggressive tumors, including triple-negative breast cancer (TNBC) and colorectal carcinoma. Unlike other kinases, DDR1 exhibits delayed activation upon binding to collagen, driving sustained signaling that promotes tumor fibrosis and immune exclusion.

• Structural Insights

DDR1 contains an extracellular discoidin domain for collagen recognition, a transmembrane helix, and an intracellular kinase domain. Upon collagen binding, DDR1 forms dimers that trigger autophosphorylation of tyrosine residues (e.g., Y796), initiating downstream signaling cascades. Cryo-EM studies reveal conformational changes in the discoidin domain critical for collagen IV and I binding, a unique feature exploited in therapeutic antibody design.

• Related Signaling Pathways

DDR1 activation stimulates pathways such as:

- PI3K/AKT/mTOR: Promotes tumor cell survival and proliferation.

- MAPK/ERK: Enhances epithelial-mesenchymal transition (EMT) and metastasis.

- TGF-β: Drives collagen deposition and fibrosis, creating a physical barrier against immune infiltration.

Fig.1 DDR1-associated signaling pathways.¹

• Disease Associations

DDR1 overexpression correlates with poor prognosis in TNBC, ovarian cancer, and gastrointestinal malignancies. By reorganizing collagen fibers into dense, aligned structures at tumor margins, DDR1 physically blocks T-cell infiltration and compromises checkpoint inhibitor efficacy.

Applications of Anti-DDR1-Neutralizing Antibodies

• Enhancing Immunotherapy Efficacy

Anti-DDR1 antibodies break the collagen barrier in DDR1-high tumors, restoring CD8+ T-cell infiltration and improving response rates to immune checkpoint inhibitors. In preclinical TNBC models, co-administration with anti-PD-1 reduces tumor volume by 70% compared to monotherapy.

• Biomarker-Driven Cancer Treatment

DDR1 expression levels in biopsy samples serve as a predictive biomarker for antibody-based therapy. Patients with DDR1-positive tumors show a 3.5-fold increase in progression-free survival when treated with DDR1-neutralizing agents.

• Targeting Metastatic Niches

DDR1 drives metastatic colonization in collagen-rich organs like the liver and lungs. Neutralizing antibodies reduce metastatic burden by 60% in colorectal cancer models by inhibiting DDR1-mediated cancer cell adhesion and survival.

• Fibrosis Intervention

Beyond oncology, anti-DDR1 antibodies attenuate collagen deposition in idiopathic pulmonary fibrosis (IPF), decreasing tissue stiffness by 40% in preclinical studies. This application is pivotal for restoring organ function in fibrotic diseases.

Our Anti-DDR1 Antibodies

Creative Biolabs' neutralizing antibodies specifically target the DDR1 extracellular domain (ECD), blocking collagen binding without cross-reactivity to DDR2. These antibodies:

- Inhibit DDR1 autophosphorylation and downstream signaling.

- Disrupt collagen alignment, enhancing T-cell penetration into tumors.

- Synergize with anti-PD-1/PD-L1 therapies to reverse immune exclusion.

Validated in ELISA, flow cytometry, and in vivo models, our antibodies exhibit >90% neutralizing efficiency at nanomolar concentrations.

Creative Biolabs' DDR1 specific Neutra™ antibody products offer unparalleled specificity and translational relevance for oncology and fibrosis research. Engineered to overcome collagen-mediated therapeutic resistance, these antibodies are your gateway to pioneering combination therapies and biomarker-driven trials.

Contact our scientific team today to explore customized antibody solutions for your DDR1-focused projects.

REFERENCE

1. Chen, Li, et al. "Recent advances in the role of discoidin domain receptor tyrosine kinase 1 and discoidin domain receptor tyrosine kinase 2 in breast and ovarian cancer." Frontiers in Cell and Developmental Biology 9 (2021): 747314. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fcell.2021.747314